Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.72 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.72 |
| ▸ | HTR1A | P08908 | 5/20 | 0.72 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.72 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.72 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.72 |
| ▸ | DRD3 | P35462 | 5/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.72 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.72 |
| ▸ | DRD1 | P21728 | 4/20 | 0.72 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.72 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.72 |
| ▸ | LMNA | P02545 | 3/20 | 0.72 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.72 |
| ▸ | SLC22A1 | O15245 | 3/20 | 0.72 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isothipendyl SCHEMBL30017997 | 1.00 | KMT2A (1.00) | KMT2ACYP2D6CHRM2HTR1ACHRM1 | |
| Isothipendyl SCHEMBL29500369 | 0.99 | KMT2A (0.97) | KMT2ACYP2D6CHRM2HTR1ACHRM1 | |
| Isothipendyl SCHEMBL230214 | 0.99 | KMT2A (0.97) | KMT2ACYP2D6CHRM2HTR1ACHRM1 | |
| Isothipendyl SCHEMBL28682222 | 0.90 | KMT2A (0.81) | KMT2ACYP2D6CHRM2HTR1ACHRM1 | |
| Isothipendyl SCHEMBL19555662 | 0.90 | KMT2A (0.81) | KMT2ACYP2D6CHRM2HTR1ACHRM1 | |
| Isothipendyl SCHEMBL6035570 | 0.89 | KMT2A (0.79) | KMT2ACYP2D6CHRM2HTR1ACHRM1 | |
| Promethazine SCHEMBL28860403 | 0.88 | KMT2A (0.77) | KMT2ACYP2D6CHRM2HTR1ACHRM1 | |
| Isothipendyl SCHEMBL28086235 | 0.85 | KMT2A (0.72) | KMT2ACYP2D6CHRM2HTR1ACHRM1 | |
| Promethazine SCHEMBL717498 | 0.84 | CYP2D6 (0.94) | KMT2ACYP2D6CHRM2HTR1ACHRM1 | |
| Promethazine SCHEMBL29362589 | 0.84 | CYP2D6 (0.94) | KMT2ACYP2D6CHRM2HTR1ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 993 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4704971-A1 | GAMMA STIMULATION AND NEUROMODULATOR COMBINATION THERAPY | Cognito Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| WO-2025082959-A1 | A PHENOTHIAZINE-RELATED COMPOUND CONJUGATED TO A PEPTIDE | UNIVERSITY OF ULSTER (GB) | 2025-04-24 | — | — | WO | claimed |
| WO-2024229174-A1 | GAMMA STIMULATION AND NEUROMODULATOR COMBINATION THERAPY | Cognito Therapeutics, Inc. (US) | 2024-11-07 | — | — | WO | claimed |
| US-20230255884-A1 | FINISHED FIBROUS SRUCTURES AND METHODS OF THEIR USE AND PREPARATION | CLEXIO BIOSCIENCES LTD. (IL) | 2023-08-17 | — | — | US | claimed |
| WO-2020222187-A1 | FINISHED FIBROUS STRUCTURES AND METHODS OF THEIR USE AND PREPARATION | CLEXIO BIOSCIENCES LTD. (IL) | 2020-11-05 | — | — | WO | claimed |
| WO-2020194308-A1 | ANTIPRURITIC COMPOSITIONS | INNOCAN PHARMA LTD. (IL) | 2020-10-01 | — | — | WO | claimed |
| US-9492541-B2 | Phenylepherine containing dosage form | SOVEREIGN PHARMACEUTICALS, LLC (US) | 2016-11-15 | — | — | US | claimed |
| US-9179994-B2 | Implantable film/mesh composite | COVIDIEN LP (US) | 2015-11-10 | — | — | US | claimed |
| US-20150216898-A1 | COMPOSITION FOR TREATING PSORIASIS | PSORIASIS+CREAMS SWENDEN AB (SE) | 2015-08-06 | — | — | US | claimed |
| US-20050266032-A1 | Dosage form containing multiple drugs | SOVEREIGN PHARMACEUTICALS, LTD. (US) | 2005-12-01 | — | — | US | claimed |
| CN-1703199-A | Aggregate with enhanced deformability comprising at least three amphiphiles for improved transport through a semi-permeable barrier and use of non-invasive drugs in vivo, in particular through the skin | IDEA AG (DE) | 2005-11-30 | — | — | CN | claimed |
| WO-2005094832-A1 | COMPOSITIONS COMPRISING MELOXICAM | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-13 | — | — | WO | claimed |
| EP-1551370-A1 | AGGREGATE WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | IDEA AG (DE) | 2005-07-13 | — | — | EP | claimed |
| US-20040105881-A1 | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2004-06-03 | — | — | US | claimed |
| WO-2004032900-A1 | AGGREGATE WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | IDEA AG (DE) | 2004-04-22 | — | — | WO | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-0152379-A2 | Process for preparing pharmaceutical compositions containing unilamellar liposomes | CIBA-GEIGY AG (CH) | 1985-08-21 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040105881-A1 | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | CUTA, ABCG2, PIGS | KMT2A 4031/4885CYP2D6 632/4885CHRM2 2986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.